La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Scholar Rock Holding Crescita futura

Future criteri di controllo 2/6

Scholar Rock Holding prevede che gli utili e i ricavi cresceranno rispettivamente di 41.2% e 65.2% all'anno. Si prevede che l'EPS crescerà di 46.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -48.7% in 3 anni.

Informazioni chiave

33.3%

Tasso di crescita degli utili

40.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.5%
Tasso di crescita dei ricavi	64.0%
Rendimento futuro del capitale proprio	-48.7%
Copertura analitica	Good
Ultimo aggiornamento	27 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01

We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Jan 05

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:SRRK - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	129	-149	-119	-65	8
12/31/2025	21	-223	-214	-218	9
12/31/2024	N/A	-233	-171	-206	9
6/30/2024	N/A	-204	-169	-169	N/A
3/31/2024	N/A	-183	-152	-152	N/A
12/31/2023	N/A	-166	-145	-145	N/A
9/30/2023	N/A	-159	-137	-137	N/A
6/30/2023	N/A	-160	-131	-131	N/A
3/31/2023	N/A	-166	-134	-133	N/A
12/31/2022	33	-135	-134	-133	N/A
9/30/2022	37	-131	-138	-136	N/A
6/30/2022	43	-125	-149	-146	N/A
3/31/2022	47	-112	-146	-143	N/A
12/31/2021	19	-132	-132	-127	N/A
9/30/2021	18	-122	-121	-114	N/A
6/30/2021	16	-109	-109	-101	N/A
3/31/2021	15	-97	-96	-89	N/A
12/31/2020	15	-86	-64	-60	N/A
9/30/2020	20	-71	-60	-57	N/A
6/30/2020	21	-64	-50	-48	N/A
3/31/2020	22	-57	-48	-45	N/A
12/31/2019	20	-51	-66	-63	N/A
9/30/2019	13	-54	6	8	N/A
6/30/2019	8	-49	12	14	N/A
3/31/2019	3	-51	17	19	N/A
12/31/2018	N/A	-49	23	25	N/A
9/30/2018	N/A	-43	-37	-37	N/A
6/30/2018	N/A	-38	-34	-33	N/A
3/31/2018	N/A	-29	N/A	-27	N/A
12/31/2017	N/A	-25	N/A	-22	N/A
12/31/2016	0	-16	N/A	-15	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che SRRK rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che SRRK rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che SRRK rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di SRRK ( 65.2% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SRRK ( 65.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che SRRK non sarà più redditizia tra 3 anni.

Scholar Rock Holding Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 8.1% to US$26.25

Price target increased by 7.1% to US$25.71

Price target increased by 9.8% to US$24.00

Price target decreased to US$22.57

Price target decreased to US$29.00

Consensus revenue estimates increase by 75%

Recent updates

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Board Member notifies of intention to sell stock

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting